

**“H2O”  
Academic Detailing  
in the Oklahoma Cooperative’s AHRQ’s  
EvidenceNOW Initiative**

**Steven A. Crawford, MD  
Co-PI, Healthy Hearts for Oklahoma  
Professor & Chair, Family & Preventive Medicine  
OU College of Medicine**

Healthy Hearts for Oklahoma (H2O)



# Relevant Disclosure and Resolution

**Under Accreditation Council for Continuing Medical Education guidelines disclosure must be made regarding relevant financial relationships with commercial interests within the last 12 months.**

**Steven A. Crawford, MD**

I have no relevant financial relationships or affiliations with commercial interests to disclose.

Healthy Hearts for Oklahoma (H2O)

The Oklahoma Cooperative for AHRQ's

EvidenceNOW



# What is H2O?


- Largest AHRQ grant
- Study to test the role of a healthcare extension service to support small & medium size primary care practices
- Emphasizes current evidence-based guidelines
- Focus on Heart Health using ABCS'
  - Effective Aspirin use
  - Blood pressure control
  - Cholesterol management using statins
  - Smoking cessation

Healthy Hearts for Oklahoma (H2O)



# Opportunities for prevention

Counties in Oklahoma have high rates of preventable CV deaths<sup>1</sup>



# 7 Regional collaboratives in 12 states

*Aligned with DHHS Healthy Hearts initiative*


*5,000 Primary Care Practices*

**Touching 8 Million lives**


**To identify best strategies for improving America's heart health**




# Build Capacity to Move Knowledge into Practice



# Support to Move Knowledge to Practice



# Support to Move Knowledge to Practice





# How were AD's incorporated into the process?

- **NaRCAD was contracted to:**
  - Provide evidence-based detailing materials
  - Conduct a two-day on-site “train the trainer” program for the selected AD's
- **The Oklahoma Center for Healthcare Improvement (OCHI) recruited clinician detailers from practice and academia – MD's, DO's, PA's, NP's**
- **Scheduled two AD visits with 250 practices**
- **Conduct on-going quarterly web-based AD education**

# How were AD's incorporated into the process?

- AD visits involved joint in-person discussions or teleconferences with clinicians and staff along with the assigned practice facilitators to review the evidence behind the ABCS guidelines
- Review what the practices were achieving and what high performing practices do
- The ultimate goal of the AD visit was to elicit targets for improvement and an improvement plan for the practice

# Blood Pressure Control in Primary Care



- Aspirin when appropriate
- Blood pressure control
- Cholesterol management
- Smoking cessation

Healthy Hearts for Oklahoma (H2O)


The Oklahoma Cooperative for AHRQ's



This document was produced by the National Resource Center for Academic Detailing (NaRCAD), supported by a grant from the Agency for Healthcare Research and Quality. These are general recommendations only; specific clinical decisions should be made by the treating physician based on an individual patient's clinical condition. Authors: Jennifer Lewey, MD, Stephen Braun, Michael Fischer, MD, MS, Arielle Mather, MPH.

## Screening and treating hypertension can improve the health of patients and the population<sup>1</sup>

Many patients don't know that they have hypertension, are not on treatment or are not controlled.



## Identifying hypertension

Accurate blood pressure measurement is critical for establishing the diagnosis. Tools to help practice staff accurately measure blood pressure can be found at <http://ophic.ouhsc.edu/rpr>

Once a patient has been identified as hypertensive, clinicians should:


- Assess lifestyle factors that can elevate blood pressure, including diet, alcohol, physical inactivity, and obesity;
- Identify other cardiovascular risk factors or concomitant disorders that will guide treatment;
- Search for identifiable secondary causes of high blood pressure;
- Determine extent of end-organ damage

Target blood pressure:  
For most patients, a goal of 140/90 should be used to guide treatment.



## JNC 8 Approach to HTN Treatment<sup>4</sup>

<sup>4</sup>Adapted from the 2014 Evidence-Based Guideline



**Lifestyle modification remains a critical component of health promotion and ASCVD risk reduction, both prior to and in concert with the use of antihypertensive medications.**

## Choosing an antihypertensive drug class

Multiple drug classes can effectively lower blood pressure. Patient characteristics should guide the initial choice.

Drug Class	Best Suited For	Risks/Concerns
Thiazide-type diuretics <sup>5,6</sup>	First-line treatment of hypertension in most patients	Monitor kidney function & potassium
ACE-I or ARB <sup>7,8</sup>	Diabetes Chronic kidney disease Congestive heart failure Ischemic heart disease	Monitor kidney function & potassium Cough with ACE-I (can switch to ARB)
CCB <sup>9</sup>	Coronary artery disease (if beta blocker intolerant)	Lower extremity edema Constipation
Beta-blockers <sup>10</sup>	Coronary artery disease Congestive heart failure	No longer first choice for uncomplicated hypertension Use with caution in obstructive pulmonary disease

Several other medication classes, including loop diuretics, potassium-sparing diuretics, alpha blockers, and direct renin inhibitors may have a role for patients requiring multiple agents to control their hypertension.

## References

- Chobanian AV, Bakris GL, Black HR, et al. The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report. *JAMA*. 2003;289(19):2560-2572.
- Wawakwo T, Yoon SS, Burt V, Gu Q. Hypertension among adults in the United States: National Health and Nutrition Examination Survey, 2011-2012. *NCHS Data Brief*. 2013 Oct;(133):1-8.
- Neal B, MacMahon S, Chapman N. Blood Pressure Lowering Treatment Trialists C. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomised trials. *Blood Pressure Lowering Treatment Trialists' Collaboration*. *Lancet*. 2000;356(9246):1955-1964.
- James PA, Oparil S, Carter BL, et al. 2014 evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). *JAMA*. 2014;311(5):507-520.
- Offices A, Coordinators for the ACESTR. Lipid-Lowering Treatment to Prevent Heart Attack T. Major outcomes in high-risk hypertensive patients randomized to angiotensin-converting enzyme inhibitor or calcium channel blocker vs diuretic: The Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT). *JAMA*. 2002;288(23):2981-2997.
- Pasy BA, Lunney T, Furlberg CD. Meta-analysis of health outcomes of chlorthalidone-based vs nonchlorthalidone-based low-dose diuretic therapies. *JAMA*. 2004;292(11):1437-44.
- Heran BS, Wong MM, Heran IK, Wright JM. Blood pressure lowering efficacy of angiotensin converting enzyme (ACE) inhibitors for primary hypertension. *Cochrane Database Syst Rev*. 2008(4):CD003823.
- Matchar DR, McCrory DC, Orlando LA, et al. Systematic review: comparative effectiveness of angiotensin-converting enzyme inhibitors and angiotensin II receptor blockers for treating essential hypertension. *Ann Intern Med*. 2008;148(1):16-29.
- McDonagh MS, K.B. Eden, and K. Peterson. Drug class review on calcium channel blockers. 2005. Oregon Evidence-based Practice Center: Oregon.

## Healthy Hearts for Oklahoma (H2O)

The Oklahoma Cooperative for AHRQ's

EvidenceNow



# Why would a practice participate in H2O?

- Help prepare for value-based payment models
- Help understand quality data about a practice
- Learn how to apply formal Quality Improvement (QI) processes in a practice
- One year of on-site assistance
- Access to current evidence-based guidelines
- Obtain community-wide data about their patients through the state's embryonic HIEO

Healthy Hearts for Oklahoma (H2O)



# Why would a practice participate in H2O?

- Apply formal QI methods to targets selected by clinician
- Provide each practice with tangible resources
  - Practice Dashboard – based on responses to surveys
  - Original measure baseline from practice's EMR & HIEO
  - Ongoing performance on targeted measures
  - Detail aids for ABCS measures
  - CME credits
  - MOC Part IV credit

# H2O Academic Detailing Findings

- Recruited 38 clinician AD's
- 30 performed at least one visit, 9 performed more than 20
- AD's valued the training, the evidence base for the guidelines, and a firsthand view of rural primary healthcare
- Recipients of AD visits valued the attention, focus on quality of care, and their practice review
- Detailer aids were copied and posted as exam room reminders
- Practice facilitators referenced AD conversations adding credibility to interventions
- Tele-communication visits were occasionally used if scheduling issues

Healthy Hearts for Oklahoma (H2O)



# H2O Support Provided to Practices


Type of Support	Contacts
<b>Academic Detailing (1)</b>	<b>242</b>
<b>Academic Detailing (2)</b>	<b>191</b>
Administration	150
Close-Out Meeting	209
EHR Data Extraction	501
Enrollment	553
Practice Facilitation	4783
Recruitment	51
Survey/Research Data	66
Technology Support	325
Withdrawal Note	13
<b>Grand Total</b>	<b>7084</b>

Healthy Hearts for Oklahoma (H2O)

The Oklahoma Cooperative for AHRQ's  
EvidenceNOW



# H2O Outcomes @ 8/20/2017 (preliminary)



Healthy Hearts for Oklahoma (H2O)





# Implications for the future?

- **Building clinician to clinician relationships makes information dissemination, guidelines adoption, and implementation of evidence-based best practices personally meaningful**
- **AD's amplify and underscore the practice facilitator's credibility**
- **Although rarely used, the AD is a peer resource for rural clinicians**
- **Travel time and complex schedules pose barriers and increase cost**
- **Standardization of the AD process can be accomplished through detailing materials, training, and continuing education**



Questions?